Continuous and bimonthly publication
ISSN (on-line): 1806-3756

Licença Creative Commons
18067
Views
Back to summary
Open Access Peer-Reviewed
Artigo Original

Multiresistant tuberculosis (MRTB): clinical, laboratorial, epidemiological, and therapeutic aspects

Tuberculose multirresistente (TBMR): aspectos clínico-laboratoriais, epidemiológicos e terapêuticos

Márcia Seiscento, Fernando Augusto Fiuza de Melo, Jorge Ide Neto, Ana Maria Lobo Noronha, Jorge Barros Afiune, Tomiko Inomata, Maria Luiza Cruz

ABSTRACT

Objectives: To evaluate clinical, laboratorial, epidemiological, and therapeutic aspects of patients presenting with multiresistant tuberculosis (MRTB). Patients and methods: From January 1993 to December 1994, a prospective, non-randomized study of patients presenting MRTB, characterized by failures under treatment schemes E-1 and E-3 according to the classification of the Brazilian Ministry of Health, and resistance to isoniazid and rifampicin was carried out. Clinical and laboratorial aspects were considered: age, gender, ethnical group, duration of condition, cavity occurrences in conventional X-rays, resistance to drugs by the indirect method according to Canetti's et al. proportional criteria; epidemiological aspects such as risk predictor factors for multiresistance and treatment results. This study consisted in two alternative chemotherapy courses combining an aminoglycoside, amikacin (Group A), or S, if sensitive (Group B), ofloxacin, clofazimine, in addition to other drugs, such as thiacetazone, ethambutol, or pyrazinamide, according to the sensitivity or to the prior limited use for a minimum of twelve months. Patients with unilateral radiologic lesions, functional possibilities, and who have accepted the indication were submitted to surgery (Group C). Treatment was at the outpatient clinic, self-administered, or under indirect supervision, with hospital admission allowed for clinical reasons, for a limited time, or when surgery was indicated. Patients with prior alternative treatment, those infected with HIV, pregnant patients, and those with renal failure were excluded from the study. Evaluation extended to twelve months after completion of treatment. Results: 70 patients with mean age of 37 years, 42 male, 44 caucasian, and 26 non-caucasian (two orientals), average duration of the condition of four years, and bilateral cavitary lesions in 55 (78.6%). Resistance to two drugs in 28.6%, 51.4% to three drugs, and 20% to four drugs. The most frequent risk predictor factor for MRTB was abandonment (54.3%) followed by recurrence after cure with treatment scheme E1 and failure at retreatment (14.3%), intolerance to drugs (11.4%), contact with MRTB (8.6%). The risk predictor factor could not be determined in 11%, acquired multiresistance being considered in 80%, and primary multiresistance in only 8.6% of the patients. Cure was observed in 25 patients of Group A (n = 39), 11 patients of Group B (n = 24), and 3 of Group C (n = 7). Only two discontinued treatment (A) and only two died during treatment (C). In the control period, three patients had recurrences (1 in A, and 2 in B), and 7 died (3 in A, 2 in B, and 2 in C). The effectiveness of Group A was 67.6% (25/37) at completion of treatment, and 64.9% during the post-treatment control. The effectiveness of Group B was 45.8% (11/24) at completion of treatment, and 37.5% during the post-treatment control. The effectiveness of Group C was 42.8% (3/7) at completion of treatment and during the post-treatment control. After twelve months, effectiveness at treatment completion in Group A fell from 64.1% to 61.5%, in Group B, it fell from 45.8% to 37.5%, and it remained unchanged in 42.8% in Group C, where the four cases of failure died. Drug discontinuation due to adverse effects occurred late in two cases, and other adverse effects were noted, but did not foster discontinuation of treatment.

RESUMO

Objetivos: Avaliar aspectos clínico-laboratoriais, epidemiológicos e terapêuticos de pacientes portadores de tuberculose multirresistente (TBMR). Pacientes e métodos: Estudo prospectivo, não randomizado, de pacientes portadores de TBMR, caracterizados pela falência aos E-1 e E-3 do Ministério da Saúde e resistência à R e H, entre janeiro de 1993 e dezembro de 1994. Foram avaliados aspectos clínico-laboratoriais como idade, sexo, grupo étnico, tempo de doença, ocorrência de cavidades na radiologia convencional, resistência às drogas pelo método indireto segundo os critérios proporcionais de Canetti et al.; epidemiológicos como os fatores preditores de riscos para a multirresistência e os resultados do tratamento. Este constou de dois regimes quimioterápicos alternativos, associando um aminoglicosídeo, amicacina (grupo A) ou a S se sensível (grupo B), a ofloxacina, a clofazimina, além de outras drogas como a tiacetazona, o E ou a Z, de acordo com a sensibilidade ou uso limitado anterior, por um mínimo de 12 meses. Doentes com lesões radiológicas unilaterais, possibilidades funcionais e que aceitaram a indicação foram submetidos a cirurgia (grupo C). O tratamento foi ambulatorial, auto-administrado ou sob supervisão indireta, com a internação admitida por razões clínicas, por tempo limitado ou quando indicada a cirurgia. Excluídos os doentes com tratamento alternativo anterior, os infectados pelo HIV, as grávidas e os portadores de insuficiência renal. A avaliação estendeu-se até 12 meses após o término do tratamento. Resultados: Estudados 70 pacientes, idade média de 37 anos, 42 do sexo masculino, 44 brancos e 26 não brancos (2 amarelos), tempo médio de doença de 4 anos e lesões cavitárias bilaterais em 55 (78,6%). Resistência a duas drogas em 28,6%, a três em 51,4% e a quatro em 20%. O fator preditor de risco para a TBMR mais freqüente foi o abandono (54,3%), seguido da recidiva após cura com E-1 e falência no retratamento (14,3%), intolerância às drogas (11,4%), contato com TBMR (8,6%). Em 11% não foi possível determinar o fator preditor de risco, sendo a multirresistência adquirida considerada em 80% e a primária, em apenas 8,6% dos casos. A cura foi observada em 25 do grupo A (N = 39), 11 do B (N = 24) e 3 do C (N = 7). Somente 2 abandonaram o tratamento (A) e apenas 2 morreram durante o tratamento (C). No período de controle, 3 recidivaram (1 no A e 2 no B) e 7 morreram (3 no A, 2 no B e 2 no C). A eficácia do grupo A foi de 67,6% (25/37) no final do tratamento e 64,9% no controle pós-tratamento; do B, de 45,8% (11/24) e 37,5%; e do C, de 42,8% (3/7) ao final e no controle. A efetividade ao final do tratamento no grupo A caiu de 64,1 para 61,5% após 12 meses; no B, de 45,8 para 37,5%; permanecendo inalterada em 42,8% no C, no qual os 4 que faliram foram a óbito. Interrupção de drogas por efeitos adversos ocorreu tardiamente em 2 casos e outras adversidades foram anotadas sem necessidade de interromper o tratamento.


THE CONTENT OF THIS ARTICLE IS NOT AVAILABLE FOR THIS LANGUAGE.


Indexes

Development by:

© All rights reserved 2024 - Jornal Brasileiro de Pneumologia